Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Jennie Z Wimperis"'
Autor:
Imran Rafi, Shamez N Ladhani, Michael P. Lewis, Jennie Z Wimperis, Paula H. B. Bolton-Maggs, John Davies
Publikováno v:
British Journal of Haematology. 155:308-317
Guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen were first published by the British Committee for Standards in Haematology (BCSH) in 1996 and formally reviewed in 2002. Although the guidelin
Autor:
Anne-Louise M Heath, Christian Wolf, Susan J. Fairweather-Tait, Mark Roe, Rob Foxall, Linda J. Harvey, Jennie Z Wimperis, Caroline A Spinks
Publikováno v:
British Journal of Nutrition. 97:544-549
Hepcidin plays a major role in iron homeostasis, but understanding its role has been hampered by the absence of analytical methods for quantification in blood. A commercial ELISA has been developed for serum prohepcidin, a hepcidin precursor, and the
Autor:
Nicholas Counsell, Sally F. Barrington, Peter Hoskin, Paul Smith, John Radford, Dominic Culligan, Alison Brownell, R. Pettengell, Peter Johnson, Andrew Lister, Jennie Z Wimperis, Andrew McMillan, Anton Kruger, Barry W. Hancock, Michael O'Doherty, Bilyana Popova, Timothy M Illidge
Publikováno v:
Radford, J, Illidge, T, Counsell, N, Hancock, B, Pettengell, R, Johnson, P, Wimperis, J, Culligan, D, Popova, B, Smith, P, McMillan, A, Brownell, A, Kruger, A, Lister, A, Hoskin, P, O'Doherty, M & Barrington, S 2015, ' Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin's Lymphoma ', New England Journal of Medicine, vol. 372, no. 17, pp. 1598-1607 . https://doi.org/10.1056/NEJMoa1408648
It is unclear whether patients with early-stage Hodgkin's lymphoma and negative findings on positron-emission tomography (PET) after three cycles of chemotherapy with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) require radiotherapy.Pa
Publikováno v:
Rheumatology. 41:176-179
Objectives. To determine the value of screening patients with inflammatory arthritis for haemochromatosis-associated mutations in the HFE gene. Methods. We screened 1000 patients with inflammatory arthritis and 1000 controls for the HFE gene mutation
Publikováno v:
Blood Cells, Molecules, and Diseases. 23:288-291
ABSTRACT: We have examined normal individuals and all the patients currently being treated for hemochromatosis at the Norfolk and Norwich hospital for mutations in the HLA-H gene. We found a gene frequency in 200 normal subjects for the 845A (C282Y)
Publikováno v:
Leukemialymphoma. 49(8)
We reviewed the outcome of 24 patients with early and advanced stage Hodgkin lymphoma (HL) treated with ABVD chemotherapy (263 treatment deliveries) without the use of G-CSF over a 3-year period. Patients received full dose ABVD regardless of the abs
Autor:
Vicky Bardsley, Jennie Z Wimperis, Gavin Willis, Barbara A. Jennings, Ray Lonsdale, Ian W Fellows
Publikováno v:
BMC Gastroenterology
BMC Gastroenterology, Vol 5, Iss 1, p 17 (2005)
BMC Gastroenterology, Vol 5, Iss 1, p 17 (2005)
Background Although most patients with hereditary haemochromatosis have HFE C282Y mutations, the lifetime risk to HFE C282Y homozygotes of developing fatal diseases such as hepatocellular carcinoma is uncertain. We have carried out a cross-sectional
EDITOR–In their recent paper, Coppin et al found surviving elderly people who were homozygous for the C282Y mutation at a frequency similar to our previous study.1 2 Their results illustrate clearly and simply that fatal disease is not an invariant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a265c95a6b20920ee4a9986c04ce8e5
https://europepmc.org/articles/PMC259203/
https://europepmc.org/articles/PMC259203/
Publikováno v:
Blood cells, moleculesdiseases. 31(2)
Most individuals diagnosed with hereditary hemochromatosis have mutations in both copies of the HFE gene, with such mutations being common in populations of north European origin. The number of individuals currently diagnosed and treated for hemochro
EDITOR—The conclusion of the letter by Allen and Williamson is based on speculation.1 They state that at least half of the individuals who are homozygous for the C282Y mutation of the HFE gene will develop symptoms and signs of haemochromatosis, bu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f87174ab56f3c0e7e7393f2c0284504
https://europepmc.org/articles/PMC1127266/
https://europepmc.org/articles/PMC1127266/